Robert A S AriÃ«ns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5415821/publications.pdf

Version: 2024-02-01

		34105	56724
144	7,830	52	83
papers	citations	h-index	g-index

146	146	146	6600
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Fibrin Clot Structure and Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, e88-99.	2.4	422
2	Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood, 2002, 100, 743-754.	1.4	322
3	The genetics of haemostasis: a twin study. Lancet, The, 2001, 357, 101-105.	13.7	266
4	Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet, The, 1997, 349, 769-771.	13.7	236
5	Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet, The, 2003, 361, 1424-1431.	13.7	187
6	Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke. Stroke, 2021, 52, 1131-1142.	2.0	185
7	The influence of type 2 diabetes on fibrin structure and function. Diabetologia, 2005, 48, 1198-1206.	6.3	181
8	Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease. Circulation, 2002, 106, 1938-1942.	1.6	172
9	Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia, 2006, 49, 1071-1080.	6.3	163
10	Diagnosis and classification of factorÂXIII deficiencies. Journal of Thrombosis and Haemostasis, 2011, 9, 1404-1406.	3.8	157
11	Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood, 2010, 115, 3980-3988.	1.4	143
12	Genetic and Environmental Determinants of Fibrin Structure and Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1558-1566.	2.4	137
13	Atomic Force Microscopy-Based Molecular Recognition of a Fibrinogen Receptor on Human Erythrocytes. ACS Nano, 2010, 4, 4609-4620.	14.6	136
14	The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. Journal of Thrombosis and Haemostasis, 2014, 12, 197-205.	3.8	136
15	Fibrin(ogen) and thrombotic disease. Journal of Thrombosis and Haemostasis, 2013, 11, 294-305.	3.8	135
16	International Registry on Factor XIII Deficiency: A basis formed mostly on European data. Thrombosis and Haemostasis, 2007, 97, 914-921.	3.4	129
17	Subunit Antigen and Activity Levels of Blood Coagulation Factor XIII in Healthy Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2012-2016.	2.4	128
18	The molecular physiology and pathology of fibrin structure/function. Blood Reviews, 2005, 19, 275-288.	5.7	126

#	Article	IF	Citations
19	Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin Î±-chain crosslinking. Blood, 2015, 126, 1940-1948.	1.4	121
20	Functional Analysis of the Fibrinogen AÎ± Thr312Ala Polymorphism. Circulation, 2003, 107, 2326-2330.	1.6	120
21	Fibrinogen gamma-chain splice variant Î³â€² alters fibrin formation and structure. Blood, 2003, 102, 535-540.	1.4	119
22	Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. Journal of Thrombosis and Haemostasis, 2015, 13, 909-919.	3.8	116
23	Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood, 2011, 118, 3942-3951.	1.4	114
24	Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet, The, 2002, 359, 667-671.	13.7	103
25	Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of Thrombosis and Haemostasis, 2016, 14, 1054-1066.	3.8	102
26	Functional analysis of fibrin Î³-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood, 2007, 110, 902-907.	1.4	101
27	Immobilized fibrinogen activates human platelets through glycoprotein VI. Haematologica, 2018, 103, 898-907.	3.5	101
28	Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 712-717.	2.4	97
29	The pleiotropic role of the fibrinogen Î³â€² chain in hemostasis. Blood, 2009, 114, 3994-4001.	1.4	91
30	The Effect of Dimethylbiguanide on Thrombin Activity, FXIII Activation, Fibrin Polymerization, and Fibrin Clot Formation. Diabetes, 2002, 51, 189-197.	0.6	90
31	A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Human Molecular Genetics, 2013, 22, 2941-2947.	2.9	88
32	A fibrin biofilm covers blood clots and protects from microbial invasion. Journal of Clinical Investigation, 2018, 128, 3356-3368.	8.2	88
33	Î±â˜†Î± Cross-Links Increase Fibrin Fiber Elasticity and Stiffness. Biophysical Journal, 2012, 102, 168-175.	0.5	85
34	Thrombus Structural Composition in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2370-2383.	2.4	83
35	Clot properties and cardiovascular disease. Thrombosis and Haemostasis, 2014, 112, 901-908.	3.4	80
36	A Variant in LDLR Is Associated With Abdominal Aortic Aneurysm. Circulation: Cardiovascular Genetics, 2013, 6, 498-504.	5.1	78

#	Article	IF	Citations
37	Fibrin and D-dimer bind to monomeric GPVI. Blood Advances, 2017, 1, 1495-1504.	5.2	72
38	Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thrombosis Research, 2021, 200, 1-8.	1.7	72
39	Common variation in the C-terminal region of the fibrinogen Î²-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood, 2008, 111, 643-650.	1.4	71
40	Roles of fibrin Î±- and Î³-chain specific cross-linking by FXIIIa in fibrin structure and function. Thrombosis and Haemostasis, 2014, 112, 842-850.	3.4	69
41	Role of Fibrin Structure in Thrombosis and Vascular Disease. Advances in Protein Chemistry and Structural Biology, 2011, 83, 75-127.	2.3	68
42	Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. British Journal of Haematology, 2002, 119, 169-175.	2.5	66
43	Fibrin clot structure in patients with end-stage renal disease. Thrombosis and Haemostasis, 2007, 98, 339-345.	3.4	66
44	Double diabetes: A distinct highâ€risk group?. Diabetes, Obesity and Metabolism, 2019, 21, 2609-2618.	4.4	65
45	A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 2487-2496.	3.8	61
46	The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood, 2000, 96, 988-95.	1.4	61
47	Genetics of fibrin clot structure: a twin study. Blood, 2004, 103, 1735-1740.	1.4	59
48	Evidence that fibrinogen Î³â€² directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. Journal of Thrombosis and Haemostasis, 2012, 10, 1072-1080.	3.8	59
49	Alterations in Fibrin Structure in Patients with Liver Diseases. Seminars in Thrombosis and Hemostasis, 2016, 42, 389-396.	2.7	59
50	Interactions between factor XIII and the Î±C region of fibrinogen. Blood, 2011, 117, 3460-3468.	1.4	56
51	Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care, 2000, 23, 703-705.	8.6	55
52	Clot Architecture Is Altered in Abdominal Aortic Aneurysms and Correlates With Aneurysm Size. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 3004-3010.	2.4	55
53	Thrombin and fibrinogen Î³â€² impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood, 2016, 127, 487-495.	1.4	53
54	Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. British Journal of Haematology, 2001, 113, 537-543.	2.5	51

#	Article	IF	Citations
55	Gender-Specific Alterations in Fibrin Structure Function in Type 2 Diabetes: Associations with Cardiometabolic and Vascular Markers. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2282-E2287.	3.6	51
56	Markers of inflammation in men with small abdominal aortic aneurysm. Journal of Vascular Surgery, 2010, 52, 145-151.	1.1	49
57	Fibrinogen and Fibrin Clot Structure in Diabetes. Herz, 2004, 29, 470-9.	1.1	48
58	Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood, 2003, 102, 25-30.	1.4	46
59	Raised Plasma Fibrinogen Concentration in Patients With Abdominal Aortic Aneurysm. Angiology, 2006, 57, 607-614.	1.8	45
60	Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2002, 14, 249-256.	1.6	41
61	Factor XIII: recommended terms and abbreviations1. Journal of Thrombosis and Haemostasis, 2007, 5, 181-183.	3.8	39
62	Roles of Low Specificity and Cofactor Interaction Sites on Thrombin during Factor XIII Activation. Journal of Biological Chemistry, 2003, 278, 32020-32026.	3.4	37
63	Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. Journal of Vascular Surgery, 2008, 48, 1497-1503.e1.	1.1	35
64	Evidence that fibrinogen Î³â€² regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. Blood, 2013, 121, 3254-3260.	1.4	35
65	The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. Haematologica, 2018, 103, 9-17.	3.5	35
66	Inhibition of thrombinâ€mediated factor V activation contributes to the anticoagulant activity of fibrinogen Î³â€². Journal of Thrombosis and Haemostasis, 2013, 11, 1669-1678.	3.8	33
67	The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thrombosis Research, 2015, 136, 474-480.	1.7	33
68	Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all?. Platelets, 2019, 30, 281-289.	2.3	32
69	The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen Î± chain. Blood, 2013, 121, 2117-2126.	1.4	31
70	Elevated fibrinogen causes thrombosis. Blood, 2011, 117, 4687-4688.	1.4	28
71	The (Patho)physiology of Fibrinogen Î³â€². Seminars in Thrombosis and Hemostasis, 2016, 42, 344-355.	2.7	28
72	Joint Linkage and Association of Six Single-Nucleotide Polymorphisms in the Factor XIII-A Subunit Gene Point to V34L As the Main Functional Locus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1914-1919.	2.4	26

#	Article	IF	Citations
73	Factor XIII Activity and Antigen Levels in Patients with Coronary Artery Disease. Thrombosis and Haemostasis, 2001, 85, 569-570.	3.4	25
74	Nanoscale Probing Reveals that Reduced Stiffness of Clots from Fibrinogen Lacking 42 N-Terminal BÎ²-Chain Residues Is Due to the Formation of Abnormal Oligomers. Biophysical Journal, 2009, 96, 2415-2427.	0.5	25
75	Insights into the composition of stroke thrombi: heterogeneity and distinct clot areas impact treatment. Haematologica, 2020, 105, 257-259.	3.5	25
76	Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with nonâ€recurrent disease. Journal of Thrombosis and Haemostasis, 2019, 17, 618-626.	3.8	24
77	Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 308-316.	2.4	23
78	Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer. Blood, 2021, 137, 3443-3453.	1.4	23
79	The Role of Fibrin(ogen) in Wound Healing and Infection Control. Seminars in Thrombosis and Hemostasis, 2022, 48, 174-187.	2.7	23
80	Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. Journal of Thrombosis and Haemostasis, 2015, 13, 2192-2201.	3.8	22
81	Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thrombosis Research, 2016, 137, 189-195.	1.7	22
82	Nonredundant Roles of Platelet Glycoprotein VI and Integrin Î±IIbÎ²3 in Fibrin-Mediated Microthrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e97-e111.	2.4	22
83	Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men. British Journal of Haematology, 2002, 118, 825-832.	2.5	21
84	Plasma thrombin-antithrombin complex, prothrombin fragments 1 and 2, and D-dimer levelsÂare elevated after endovascular but not open repair of infrarenal abdominal aortic aneurysm. Journal of Vascular Surgery, 2013, 57, 1512-1518.	1.1	21
85	Novel mechanisms that regulate clot structure/function. Thrombosis Research, 2016, 141, S25-S27.	1.7	21
86	Cardiovascular disease and heritability of the prothrombotic state. Blood Reviews, 2009, 23, 67-78.	5.7	20
87	Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. Blood, 2011, 117, 6694-6701.	1.4	19
88	CVD risk factors are related to plasma fibrin clot properties independent of total and or Î³â€™ fibrinogen concentration. Thrombosis Research, 2014, 134, 963-969.	1.7	19
89	GPVI (Glycoprotein VI) Interaction With Fibrinogen Is Mediated by Avidity and the Fibrinogen Î±C-Region. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1092-1104.	2.4	19
90	A collaborative study to establish the 1st International Standard for factor XIII plasma. Journal of Thrombosis and Haemostasis, 2007, 5, 1923-1929.	3.8	17

#	Article	IF	Citations
91	Alteration of fibrin clot properties by ultrafine particulate matter. Thrombosis and Haemostasis, 2010, 103, 103-113.	3.4	17
92	Fibrinogen Î³â€² increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood, 2014, 124, 1531-1538.	1.4	17
93	Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network. Thrombosis and Haemostasis, 2016, 116, 897-903.	3.4	17
94	Fibrin clot structure is affected by levels of particulate air pollution exposure in patients with venous thrombosis. Environment International, 2016, 92-93, 70-76.	10.0	17
95	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. Blood, 2019, 133, 1233-1244.	1.4	17
96	A study of human coagulation factor XIII A-subunit by electrospray ionisation mass spectrometry. Rapid Communications in Mass Spectrometry, 2000, 14, 1607-1611.	1.5	15
97	Fibrinogen Î±Câ€•regions are not directly involved in fibrin polymerization as evidenced by a â€œDoubleâ€Detroitâ€•recombinant fibrinogen mutant and knobsâ€•mimic peptides. Journal of Thrombosis and Haemostasis, 2020, 18, 802-814.	3.8	15
98	Fibrinolysis in Acute and Chronic Cardiovascular Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 490-505.	2.7	15
99	Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. Journal of Thrombosis and Haemostasis, 2015, 13, 795-801.	3.8	14
100	Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. Thrombosis Research, 2016, 137, 85-91.	1.7	14
101	The Relation Between Insulin Resistance and Hemostasis: Pleiotropic Genes and Common Environment. Twin Research and Human Genetics, 2003, 6, 152-161.	1.0	14
102	Ranking reactive glutamines in the fibrinogen Î±C region that are targeted by blood coagulant factor XIII. Blood, 2016, 127, 2241-2248.	1.4	13
103	Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). Journal of Thrombosis and Haemostasis, 2017, 15, 1834-1844.	3.8	13
104	Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen Î³â€² as thrombomobulin II. Matrix Biology, 2017, 60-61, 8-15.	3.6	13
105	Fibrinogen Î±C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis. ELife, 2021, 10, .	6.0	13
106	Coagulation Factor XIII-A Subunit Missense Mutation in the Pathobiology of Autosomal Dominant Multiple Dermatofibromas. Journal of Investigative Dermatology, 2020, 140, 624-635.e7.	0.7	12
107	Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1269-1281.	2.3	12
108	Regarding â€œAltered fibrin clot structure and function in individuals with intermittent claudicationâ€• Journal of Vascular Surgery, 2009, 49, 1088-1089.	1.1	11

#	Article	IF	Citations
109	Partial deletion of the Î±C-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis. Thrombosis and Haemostasis, 2013, 110, 1135-1144.	3.4	11
110	Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thrombosis and Haemostasis, 1999, 81, 203-7.	3.4	11
111	Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. American Journal of Cardiology, 2000, 85, 527-531.	1.6	10
112	The alpha-2-antiplasmin Arg407Lys polymorphism is associated with Abdominal Aortic Aneurysm. Thrombosis Research, 2014, 134, 723-728.	1.7	10
113	Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A. FEBS Journal, 2020, 287, 452-464.	4.7	10
114	Elimination of fibrin Î³-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2103226118.	7.1	10
115	A new red cell shape helps the clot. Blood, 2014, 123, 1442-1443.	1.4	9
116	Effects of riboflavin and amotosalen photoactivation systems for pathogen inactivation of freshâ€frozen plasma on fibrin clot structure. Transfusion, 2016, 56, 41-48.	1.6	9
117	High fibrinogen Î³â€² levels in patient plasma increase clot formation at arterial and venous shear. Blood Advances, 2021, 5, 3468-3477.	5.2	9
118	Automated Fiber Diameter and Porosity Measurements of Plasma Clots in Scanning Electron Microscopy Images. Biomolecules, 2021, 11, 1536.	4.0	9
119	Vascular Dementia and Crosstalk Between the Complement and Coagulation Systems. Frontiers in Cardiovascular Medicine, 2021, 8, 803169.	2.4	9
120	Clot Structure and Fibrinolysis in Thrombosis and Hemostasis. BioMed Research International, 2017, 2017, 1-2.	1.9	8
121	Impaired factor XIII activation in patients with congenital afibrinogenemia. Haematologica, 2019, 104, e111-e113.	3.5	8
122	Quantitative analysis of clot density, fibrin fiber radius, and protofibril packing in acute phase myocardial infarction. Thrombosis Research, 2021, 205, 110-119.	1.7	8
123	Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans. Thrombosis Research, 2014, 134, 78-83.	1.7	7
124	The role of Î²-barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit. Journal of Thrombosis and Haemostasis, 2018, 16, 1391-1401.	3.8	6
125	Urban Particulate Matter Induces Changes in Gene Expression in Vascular Endothelial Cells that Are Associated with Altered Clot Structure In Vitro. Thrombosis and Haemostasis, 2018, 118, 266-278.	3.4	6
126	On the localization of the cleavage site in human alphaâ€2â€antiplasmin, involved in the generation of the nonâ€plasminogen binding form. Journal of Thrombosis and Haemostasis, 2020, 18, 1162-1170.	3.8	6

#	Article	IF	Citations
127	Assessment and determinants of whole blood and plasma fibrinolysis in patients with mild bleeding symptoms. Thrombosis Research, 2019, 174, 88-94.	1.7	5
128	Contribution of Red Blood Cells and Clot Structure to Thrombosis. Blood, 2015, 126, SCI-15-SCI-15.	1.4	5
129	The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun. Journal of Thrombosis and Haemostasis, 2005, 3, 649-650.	3.8	4
130	Denser matters. Blood, 2009, 114, 3978-3979.	1.4	4
131	Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms. PLoS ONE, 2017, 12, e0177117.	2.5	4
132	A Comparative Assessment Study of Known Small-molecule GPVI Modulators. ACS Medicinal Chemistry Letters, 2022, 13, 171-181.	2.8	4
133	Fibrin protofibril packing and clot stability are enhanced by extended knob-hole interactions and catch-slip bonds. Blood Advances, 2022, , .	5.2	4
134	Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12715.	2.3	4
135	Common FXIII and Fibrinogen Polymorphisms in Abdominal Aortic Aneurysms. PLoS ONE, 2014, 9, e112407.	2.5	3
136	BÎ²Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. Thrombosis and Haemostasis, 2017, 117, 295-302.	3.4	3
137	The ₉₅RGD₉₇ sequence on the Aα chain of fibrinogen is essential for binding to its erythrocyte receptor. International Journal of Nanomedicine, 2018, Volume 13, 1985-1992.	6.7	3
138	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American Journal of Hematology, 2020, 95, 944-952.	4.1	3
139	High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thrombosis and Haemostasis, 1999, 82, 1020-3.	3.4	3
140	Getting to grips with complexity of disease will make genomics useful in arterial thrombosis. Journal of Thrombosis and Haemostasis, 2007, 5, 450-453.	3.8	1
141	Changes to the structure of blood clots formed in the presence of fine particulate matter. Journal of Physics: Conference Series, 2009, 151, 012029.	0.4	1
142	Allele-specific alternative splicing; the tail of FXIII-B tells its own tale. Journal of Thrombosis and Haemostasis, 2009, 7, 1081-1083.	3.8	0
143	Counting 1 fibrin molecule at a time. Blood, 2013, 121, 1251-1252.	1.4	0
144	Thrombosis and Hemostasis--First North Sea Conference. 12-17 June 2000, Maastricht, The Netherlands. IDrugs: the Investigational Drugs Journal, 2000, 3, 1158-61.	0.7	0